Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 75 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Radio Hosts Test Sanity For Charity By Listening to ‘Baby Shark’... November 20, 2019 Licorice: The Unique Root With 10 Amazing Health Benefits August 21, 2019 K9 Police Officer In Berlin Beats Breast Cancer For Second Time March 7, 2019 Why the Fear of Cancer Recurrence Is Often Misunderstood and How... December 6, 2022 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria New Drugs Raise Old Questions about Treating Cancer during Pregnancy Is there a future without Pap testing? Erdafitinib Prolongs Survival in Patients with Metastatic Urothelial Carcinoma and FGFR...
